Aytu BioPharma (NASDAQ:AYTU – Get Rating) and Dynavax Technologies (NASDAQ:DVAX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
Profitability
This table compares Aytu BioPharma and Dynavax Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ayut BioPharma | -33.11% | -51.52% | -16.20% |
| Dynavax Technologies | 35.99% | 45.49% | 23.65% |
Analyst Ratings
This is a summary of current ratings and target prices for Aytu BioPharma and Dynavax Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ayut BioPharma | 0 | 0 | 2 | 0 | 3.00 |
| Dynavax Technologies | 0 | 0 | 3 | 0 | 3.00 |
Aytu BioPharma presently has a consensus price target of $6.00, indicating a potential upside of 257.14%. Dynavax Technologies has a consensus price target of $24.00, indicating a potential upside of 114.29%. Given Aytu BioPharma’s higher probable upside, equity research analysts simply believe Aytu BioPharma is more favorable than Dynavax Technologies.
Insider & Institutional Ownership
19.6% of Aytu BioPharma shares are held by institutional investors. Comparatively, 94.3% of Dynavax Technologies shares are held by institutional investors. 4.3% of Aytu BioPharma shares are held by insiders. Comparatively, 2.6% of Dynavax Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuations & Earnings
This table compares Aytu BioPharma and Dynavax Technologies’ top-line revenue, earnings per share (EPS) and valuation.
| GrossRevenues | Price/Sales Ratio | NetIncome | Earnings Per Share | Price/Earnings Ratio | |
| Ayut BioPharma | $96.67 million | 0.07 | -$110.17 million | ($15.08) | -0.11 |
| Dynavax Technologies | $722.68 million | 1.98 | $293.16 million | $1.56 | 7.18 |
Dynavax Technologies has higher revenue and earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Aytu BioPharma has a beta of -0.4, suggesting that its stock price is 140% less volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
Summary
Dynavax Technologies beats Aytu BioPharma on 11 of the 13 factors compared between the two stocks.
About Aytu BioPharma
(Get Rating)
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Carbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
About Dynavax Technologies
(Get Rating)
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Receive News & Ratings for Aytu BioPharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aytu BioPharma and related companies with MarketBeat.com’s FREE daily email newsletter.